Bioventus Inc (NASDAQ:BVS) price on Friday, March 21, fall -0.92% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $9.65.
A look at the stock’s price movement, the close in the last trading session was $9.74, moving within a range at $9.495 and $9.78. The beta value (5-Year monthly) was 0.863. Turning to its 52-week performance, $14.38 and $3.90 were the 52-week high and 52-week low respectively. Overall, BVS moved -3.02% over the past month.
Bioventus Inc’s market cap currently stands at around $790.76 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-10.
Analysts have a consensus estimate of 122.71M for the company’s revenue for the quarter, with a low and high estimate of 121M and 124.02M respectively. The average forecast suggests down to a -5.21% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 564.86M, representing a -1.47% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that BVS is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 1 recommend BVS as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Hold which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
BVS’s current price about -1.98% and -4.14% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 46.58, while 7-day volatility ratio is 4.51% and 5.56% in the 30-day chart. Further, Bioventus Inc (BVS) has a beta value of 0.88, and an average true range (ATR) of 0.57. Analysts have given the company’s stock an average 52-week price target of $12, forecast between a low of $12 and high of $12. Looking at the price targets, the low is -24.35% off current price level while to achieve the yearly target high, price needs to move -24.35%. Nonetheless, investors will most likely welcome a -24.35% jump to $12 which is the analysts’ median price.
If we refocus on Bioventus Inc (NASDAQ:BVS), historical trading data shows that trading volumes averaged 0.58 over the past 10 days and 322.12K over the past 3 months. The company’s latest data on shares outstanding shows there are 65.76 million shares.
The 31.68% of Bioventus Inc’s shares are in the hands of company insiders while institutional holders own 49.30% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 0.79 million on 2025-02-28, giving us a short ratio of 3.29. The data shows that as of 2025-02-28 short interest in Bioventus Inc (BVS) stood at 177.0 of shares outstanding, with shares short falling to 0.81 million registered in 2025-01-31. Current price change has pushed the stock -8.10% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the BVS stock continues to rise going into the next quarter.
